

MASTER'S THESIS

Modulation of N-methyl-D-aspartate receptor expression in neuronal cell culture

Lui, Pik Wa

Date of Award:
2002

[Link to publication](#)

General rights

Copyright and intellectual property rights for the publications made accessible in HKBU Scholars are retained by the authors and/or other copyright owners. In addition to the restrictions prescribed by the Copyright Ordinance of Hong Kong, all users and readers must also observe the following terms of use:

- Users may download and print one copy of any publication from HKBU Scholars for the purpose of private study or research
- Users cannot further distribute the material or use it for any profit-making activity or commercial gain
- To share publications in HKBU Scholars with others, users are welcome to freely distribute the permanent URL assigned to the publication

**Modulation of N-methyl-D-aspartate Receptor Expression in
Neuronal Cell Culture**

LUI Pik Wa

A thesis submitted in fulfillment of the requirements

for the degree of

Master of Philosophy

Principal Supervisor: Dr. YUNG Kin Lam

Hong Kong Baptist University

December 2002

Abstract

N-methyl-D-aspartate (NMDA) receptors are known to play important roles in neuronal growth and development as well as in glutamate excitotoxicity that results in neuronal cell death. Excitotoxic cell death is suggested to be one of the major causes of human neurological diseases. NMDA receptors are ionotropic glutamate receptors and they are composed of heteromeric subunits (NR1, NR2A-D and NR3). A functional NMDA receptor is known to be composed of NR1 subunit coupled to at least one form of NR2 subunits. The functional properties of the NMDA receptors depend on their subunit compositions. NMDA receptors are one of the most important groups of glutamate receptors in neurons of the rat basal ganglia, a group of subcortical nuclei that is associated with movement. The neostriatum and the substantia nigra are two principal regions of the basal ganglia. Neuronal cell death in these two regions is known to cause Huntington's and Parkinson's disease respectively.

In the first part of the present study, developmental expression and functional properties of NMDA receptors in cultured striatal and nigral neurons were studied. Both striatal and nigral neurons were found to express NR1 mRNA and immunoreactivity at different time frames. In addition, striatal neurons were found to express NR1, NR2A, NR2B and NR2D mRNA and immunoreactivity whereas nigral neurons were found to express NR1, NR2B and NR2D. Patch clamp experiments revealed that only the striatal neurons but not the nigral neurons in culture displayed functional NMDA channels. Striatal neurons but not the nigral neurons were also found to respond to NMDA-induced excitotoxicity. These results indicate that different types of neurons of the basal ganglia display different intrinsic programs of

NMDA receptor expressions that may form NMDA receptors with different functional properties.

Based on the above results, striatal neurons were selected as a model to study the effects of modulation of gene expression of NMDA receptor subunit. The second part of the present study was to investigate the aftermath effects on NMDA receptor expression and functional properties after selective gene knockdown of NR1 subunit in the striatal neurons in culture. Striatal neurons were treated with a single dose of antisense oligonucleotides specific for NR1 (ANR1), sense oligonucleotides specific for NR1 or a randomized sequence based on NR1 sequence. Decreases in expression of NR1 mRNA and proteins were found only after ANR1 treatments but not in the other control treatments. There was no modification of the NR2 subunit expression after ANR1 application. Interestingly, application of ANR1 was found to provide neuroprotective effects to the striatal neurons against NMDA-induced excitotoxicity. Moreover, NMDA channel-mediated peak inward currents were found to be reduced after the application of ANR1. The present data suggest that ANR1 is an effective and useful tool in performing selective gene knockdown of NR1 subunit in striatal neurons. As a potential neuroprotective agent, ANR1 may be developed into a potent agent for treatment of neurological diseases.

Table of Contents

Declaration	i
Abstract	ii
Acknowledgements	iv
Table of Contents	v
List of Tables	xii
List of Figures	xiii
List of Abbreviations	xv
Chapter 1 Literature Review	1
1.1 The basal ganglia	1
1.1.1 Nuclei of basal ganglia	2
1.1.2 The basal ganglia circuitry: anatomical connectivity and neurotransmitters	3
1.1.2.1 Synaptic inputs to the basal ganglia	3
1.1.2.2 Indirect and direct pathways of the basal ganglia	3
1.1.2.3 Synaptic outputs from the basal ganglia	4
1.1.2.4 Dopaminergic pathway in the basal ganglia	5
1.1.3 Neostriatum	5
1.1.3.1 Neuronal subpopulation in the neostriatum	5
1.1.3.2 Medium spiny neurons	6
1.1.3.3 Striatal interneurons	7
1.1.4 Substantia nigra	9
1.2 Glutamate and glutamate receptors in the basal ganglia	10
1.2.1 NMDA receptors	11
1.2.2 Localization of the NMDA receptors in the neostriatum and substantia nigra	14
1.2.3 Glutamate excitotoxicity	14

1.3 Parkinson's disease	16
1.3.1 Cause and pathogenesis of Parkinson's disease	16
1.3.2 Overactivity of glutamate after the onset of Parkinson's disease	17
1.3.3 Treatments of Parkinson's disease	18
1.3.3.1 Levodopa (L-dopa) therapy	18
1.3.3.2 Neurosurgery	19
1.3.3.3 Blockage of glutamate receptors as a therapy of Parkinson's disease	20
1.3.3.3.1 Blockage of glutamate receptors by antagonists	20
1.3.3.3.2 Blockage of glutamate receptors by antagonists	21
1.4 Objectives of the present thesis	23
Chapter 2 Methodology	25
2.1 Overall sequence of procedures	25
2.2 Animals	25
2.3 Primary cell culture	26
2.4 Reverse transcriptase – polymerase chain reaction	26
2.4.1 Total RNA preparation	26
2.4.2 First strand cDNA synthesis	27
2.4.3 PCR assay	28
2.5 Semi-quantitative analysis of RT-PCR results	29
2.6 Double immunofluorescence	29
2.7 Control for immunocytochemistry	31
2.8 Western blot analysis	32
2.9 Semi-quantitative analysis of western blot results	33
2.10 NMDA toxicity assay	33
2.11 Patch clamp experiments	34

Chapter 3 Differential expression of endogenous N-methyl-D-aspartate receptors in striatal and nigral neurons in primary cell culture	35
3.1 Introduction	35
3.2 Objectives	37
3.3 Experimental procedures	38
3.3.1 Primary cell culture of striatal and nigral neurons	38
3.3.2 Flow cytometric analysis of substantia nigral neurons	39
3.3.3 RT-PCR assay and semi-quantitative analysis of RT-PCR results	39
3.3.4 Double immunofluorescence and semi-quantitative analyses of the intensity of immunofluorescence	40
3.3.5 Control for immunofluorescence	41
3.3.6 NMDA toxicity assay	42
3.3.7 Patch clamp experiments	43
3.3.7 Patch clamp experiments combined with immunofluorescence	43
3.4 Results	45
3.4.1 Striatal and nigral neurons in culture	45
3.4.2 Percentage of nigral neurons in culture	45
3.4.2 Expression of NR mRNAs during development	45
3.4.3 Expression of NR immunoreactivity in striatal neurons	47
3.4.5 Expression of NR immunoreactivity in nigral neurons	48
3.4.6 NMDA toxicity tests on striatal and nigral neurons	49
3.4.7 Electrophysiological studies on striatal and nigral neurons during development <i>in vitro</i>	50
3.5 Discussion	51
3.5.1 Importance of NMDA receptors to growth and development of neurons	51
3.5.2 Intrinsic differences in NR expression: a comparison between striatal and nigral neurons in culture	52

3.5.2.1 Heterogeneity of NR subunits	52
3.5.2.2 Different time frames in NR expression	54
3.5.2.3 Striatal neurons display fully functional NMDA receptor after 7 DIV	56
3.6 Conclusion	58
Figure 3.1 mRNA expression of NMDA subunits in the rat striatal neurons	59
Figure 3.2 mRNA expression of NMDA subunits in the rat nigral neurons	60
Table 3.1 Semi-quantitative analysis of the relative intensity of NMDA subunits mRNA expression in the rat striatal and nigral neurons	61
Figure 3.3 Color fluorescent micrographs of striatal neurons double immunostained to reveal immunoreactivity for NR1 together with immunoreactivity for GAD	62
Figure 3.4 Color fluorescent micrographs of striatal neurons double immunostained to reveal immunoreactivity for NR2A together with immunoreactivity for GAD	63
Figure 3.5 Color fluorescent micrographs of striatal neurons double immunostained to reveal immunoreactivity for NR2B together with immunoreactivity for GAD	64
Figure 3.6 Color fluorescent micrographs of striatal neurons double immunostained to reveal immunoreactivity for NR2D together with immunoreactivity for GAD	65
Figure 3.7 Color fluorescent micrographs of nigral neurons double immunostained to reveal immunoreactivity for NR1 and NR2B together with immunoreactivity for TH	66
Figure 3.8 Color fluorescent micrographs of nigral neurons double immunostained to reveal immunoreactivity for NR2D together with immunoreactivity for TH	67
Figure 3.9 NMDA neurotoxicity in striatal neurons during development in culture	68
Figure 3.10 NMDA neurotoxicity in nigral neurons during development in culture	69
Figure 3.11 Color fluorescent micrographs of striatal and nigral neurons double immunostained to reveal immunoreactivity for GAD and TH respectively together with immunoreactivity for Avidine	70
Figure 3.12 Whole-cell peak inward current of striatal and nigral neurons in exposing to 50 μ M NMDA	71

Chapter 4 Selective gene knockdown of NR1 subunit affects NMDA receptor expression and physiology in striatal neurons	72
4.1 Introduction	72
4.2 Objectives	75
4.3 Experiment procedures	76
4.3.1 Primary cultures of striatal neurons	76
4.3.2 Preparation of oligonucleotides and treatments	76
4.3.3 RT-PCR assay and semi-quantitative analyses of RT-PCR results	77
4.3.4 Western blot analysis and Semi-quantitative analyses of the results	78
4.3.5 Double immunofluorescence and semi-quantitative analyses of the intensity of immunofluorescence	79
4.3.6 Control for immunocytochemistry	80
4.3.7 NMDA toxicity assay	80
4.3.8 Patch clamp	81
4.3.8 Patch clamp experiments combined with immunofluorescence	82
4.4 Results	83
4.4.1 Effects of ANR1 treatments on the gene expression of NMDA receptor subunits in the cultured striatal neurons	83
4.4.2 Effects of ANR1 treatments on the expression of NR1 in total striatal protein homogenate	84
4.4.2.1 Western blot analysis	84
4.4.2.2 immunofluorescence	84
4.4.3 Effects of ANR1 treatments on phosphorylation of NR1 in total striatal protein homogenate	85
4.4.3.1 Western blot analysis	85
4.4.3.2 immunofluorescence	85
4.4.4 Effects of ANR1 treatments on the degree of NMDA-induced neuronal cell death	86

4.4.5 Effects of ANR1 treatments on the physiology of NMDA receptor in striatal neurons	87
4.5 Discussion	88
4.5.1 Down-regulation of NR1 expression by ANR1	88
4.5.2 Effects of ANR1 on NMDA receptor physiology	90
4.5.3 Neuroprotective action of ANR1 against NMDA toxicity	92
4.5.4. Effects of ANR1 on the phosphorylation of NMDA receptors at s896 and s897	93
4.6 Conclusion	94
Figure 4.1 Co-amplification of NR1, NR2 subunits and G3PDH in the ANR1 treated striatal and control neurons	95
Table 4.1 Semi-quantitative analysis of the relative intensity of NR1 and NR2A-D mRNA expression after different treatments in the striatal neurons.	96
Figure 4.2 Western blotting analyses of the levels of NR1 proteins in the ANR1, RNR1, SNR1 treated striatal and control neurons	97
Figure 4.3 Color fluorescent micrographs of ANR1 treated striatal neurons double immunostained to reveal immunoreactivity for NR1 together with immunoreactivity for GAD	98
Figure 4.4 Western blotting analyses of the levels of anti-phospho-NR1 (CT), anti-phospho-NR1 (s896) and anti-phospho-NR1 (s897)NR1 proteins in the ANR1, RNR1, SNR1 treated striatal and control neurons	99
Figure 4.5 Color fluorescent micrographs of ANR1, RNR1, SNR1 treated striatal and control neurons double immunostained to reveal immunoreactivity for anti-phospho-NR1 (CT), anti-phospho-NR1 (s896) and anti-phospho-NR1 (s897)NR1 together with immunoreactivity for GAD	100
Figure 4.6 NMDA neurotoxicity in ANR1 treated striatal neurons	101
Figure 4.7 Color fluorescent micrographs of ANR1 treated striatal double immunostained to reveal immunoreactivity for GAD together with immunoreactivity for Avidine	102
Figure 4.8 Whole-cell peak inward current of ANR1 treated striatal neurons in exposing to 50 μ M NMDA	103
Chapter 5 Antisense oligonucleotides specific for NR1: a potential agent for treating neurological diseases?	104
Reference List	105

Appendix I	121
Appendix II	123
Appendix III	124
Appendix IV	125
Curriculum Vitae	128
List of Publications	129